Endo USA

CompanyUnited States

Endo USA develops 2 assets, the furthest approved (testosterone in hormone deficiency). Mostly small molecule acting on AR and lipid and ceramide metabolism; based in the United States.

2
Assets
Furthest: Approved; 6
Trials: 2
Signals

Pipeline

testosterone
Oral testosterone replacement therapy acting as an androgen receptor agonist.
Approved, Small molecule, Lipid and ceramide metabolism, AR, hormone deficiency, hypoactive sexual desire disorder
testosterone undecanoate
Provides sustained testosterone replacement, activating androgen receptors to restore androgen-dependent functions.
Phase 3, Small molecule, AR, hypogonadism, male hypogonadism

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

Evidence behind the mechanisms4
Trials9
Signals2
Similar companies6

Updated 10 Oct 2026 · 85 sources